Cellectar Biosciences Inc. | Stock Discussion Forums

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical
Cellectar Biosciences Inc.

An SI Board Since November 2016

Posts	SubjectMarks	Bans
46	5	0

Emcee: malandavid	Type: Unmoderated

Introduction Compact

Go to reply# or date (mm/dd/yy):

Reply	Message Preview	From	Recs	Posted
21	Cellectar Biosciences Announces Successful Conjugation of Multiple Pierre Fabre	malandavid	-	11/22/2016
20	The Company’s PDC product portfolio includes CLR 131, CLR 125, CLR 124, CLR 1502	johnmartin	-	11/22/2016
19	Cellectar Biosciences Announces INC Research as the CRO for the Phase II Trial	malandavid	-	11/22/2016
18	Snce April 18, 2016 Cellectar Biosciences Inc.has outperformed by 18.11% in the	malandavid	-	11/22/2016
17	Come on don't just stroll around and invest...!!	malandavid	-	11/22/2016
16	Don't you think that it the stocks are going down gradually?	johnmartin	-	11/22/2016
15	How dose it sound promising??	johnmartin	-	11/22/2016
14	The stock of Cellectar Biosciences Inc (NASDAQ:CLRB) is a huge mover today! A	malandavid	-	11/22/2016
13	Currently trading at $2.28, can buy next week probably	malandavid	-	11/22/2016
12	In both August and September, CLRB received non-dilutive funding in the form of	johnmartin	-	11/22/2016
11	The results of the Presidential Elections will have favoring results for the co	Douglas Hall	-	11/21/2016
10	So as per the August and September Reports of the stock and the present status w	Douglas Hall	-	11/21/2016
9	Since the beginning of the year, CLRB is trading down significantly from its 52-	johnmartin	-	11/21/2016
8	[graphic] the report for the stock for the past day	Douglas Hall	-	11/21/2016
7	The company has recently announced it's successful conjugation of multiple,	johnmartin	-	11/21/2016
6	I totally agree with johnmartin about his suggestion for investing in the compan	Douglas Hall	-	11/21/2016
5	Stock currently priced at $2.33	James Donovan	-	11/21/2016
4	You are absolutely right. This is one of those stocks which even after being a p	Douglas Hall	-	11/21/2016
3	The company is trading above its 50-day moving averages of 2.15 and up from 200-	johnmartin	-	11/21/2016
2	I dont usually go into biotech but this company even being a penny stock looks p	James Donovan	-	11/21/2016
1	I have been watching the stock for the past few days and have noticed that the s	Douglas Hall	-	11/21/2016

Go to reply# or date (mm/dd/yy):